吉非替尼对中、晚期非小细胞肺癌患者血清MMP-7、MMP-9表达的影响  

Effect of Gefitinib on the Expression of Serum MMP-7, MMP-9 from Patients with Medium and Advanced Non-small Cell Lung Cancer

作　　者：方利洲[1] 刘凌[1] 张剑青[1] 梁晓[2] 

机构地区：[1]昆明医科大学第一附属医院,呼吸内二科,昆明650032 [2]云南省第一人民医院,感染性疾病科,昆明650031

出　　处：《基因组学与应用生物学》2016年第11期2909-2915,共7页Genomics and Applied Biology

基　　金：云南省卫生科技计划项目(2016NS045)资助

摘　　要：为了研究吉非替尼对中、晚期非小细胞肺癌(NSCLC)患者血清基质金属蛋白酶-7(MMP-7)、血清基质金属蛋白酶-9(MMP-9)表达的影响。本研究选取2014年9月至2015年8月本院收治的60例中、晚期NSCLC患者,根据随机数表法分为对照组30例和实验组30例。所有患者均采取营养、镇痛等对症支持治疗,对照组在此基础上采用GP方案,在第1~3天静脉滴注25 mg/m^2的顺铂,在第1天、第8天静脉滴注1 000 mg/m^2的吉西他滨;实验组在对症支持治疗基础上予以吉非替尼,口服,250 mg/次,1次/d,所有患者均以4周为1个治疗周期。观察患者治疗前和治疗1个周期后MMP-7、MMP-9表达情况,两组患者的不良反应率与临床疗效之间比较。通过治疗分析后,实验组的临床疗效率显著高于对照组,93.33%(28/30)比70.00%(21/30)(p<0.05)。实验组的血清MMP-7、MMP-9表达显著低于对照组,(0.27±0.07)ng/m L比(0.64±0.04)ng/m L,(270.92±30.24)ng/m L比(335.88±31.01)ng/m L(p<0.05)。实验组的不良反应率显著低于对照组,6.67%(2/30)比30.00%(9/30)(p<0.05)。研究结果表明在治疗中、晚期NSCLC患者中,吉非替尼能明显降低MMP-7、MMP-9的表达,临床疗效显著,安全性高。To study the effect of gefitinib on the expression of serum matrix metalloproteinases-7 （MMP-7）, matrix metalloproteinases-9 （MMP-9） from patients with medium and advanced non-small cell lung cancer （NSCLC）, we selected 60 cases of patients with medium and advanced NSCLC in our hospital from September 2014 to August 2015. We divided them into control group 30 cases and treatment group 30 cases according to the random number table method. We used symptomatic supportive treatment such as nutrition, analgesia to treat all patients. On this basis, we chose GP project for the control group, which was intravenous infusion 25 mg/m： of cisplatin in 1-3 days, intravenous infusion 1 000 mg/m^2 of gemcitabine at first day and eighth day. On the basis of symptom- atic supportive treatment, we used gefitinib in treatment group, which was taken orally, 250 mg/time, once a day. All the patients were treated with 4 weeks as 1 cycle of treatment. We observed the expression of MMP-7, MMP-9 before and after 1 cycle of treatment, and compared the adverse reaction rate and the clinical effect of the two groups. After treatment analysis, the clinical efficacy rate of the treatment group rate was significantly higher than that of the control group, which was 93.33% （28/30） versus 70.00% （21/30） （p〈0.05）. The expression of serum MMP-7, MMP-9 of the treatment group was significantly lower than that of the control group, which were （0.27±0.07） ng/mL versus （0.64±0.04） ng/mL, （270.92±30.24） ng/mL versus （335.88±31.01） ng/mL （p〈0.05）. The adverse reaction rate of the treatment group was significantly lower than that of the control group, which was 6.67% （2/30） versus 30.00% （9/30） （p 〈0.05）. The results showed that in the treatment of medium and advanced NSCLC patients, gefitinib would obviously decrease the expression of MMP-7, MMP-9, and had significant clinical curative effect distinct and high safety.

关 键 词：吉非替尼 非小细胞肺癌 基质金属蛋白酶 

分 类 号：R734.2[医药卫生—肿瘤]